Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02607956 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 657
- Enrollment target
NCT02607956 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 657 participants.
The verdict
NCT02607956, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 657 participants
- Enrollment target
Study Summary
This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.
Interventions
- DRUG B/F/TAF
- DRUG F/TAF
- DRUG F/TAF Placebo
- DRUG DTG
- DRUG DTG Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 657 participants |
| Start Date | 2015-11-11 |
| Est. Completion | 2021-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02607956
The ClinicalTrials.gov registry entry for NCT02607956 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 657 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which B/F/TAF is the first listed.
NCT02607956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02607956 about?
NCT02607956 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults". This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment...
What is the current status of trial NCT02607956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 657 participants. The study started on 2015-11-11. Estimated completion is 2021-07-05.
What interventions are being tested in trial NCT02607956?
The interventions under investigation include: B/F/TAF (DRUG), F/TAF (DRUG), F/TAF Placebo (DRUG), DTG (DRUG), DTG Placebo (DRUG).
Who is sponsoring clinical trial NCT02607956?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.